<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309387</url>
  </required_header>
  <id_info>
    <org_study_id>NEI-110</org_study_id>
    <nct_id>NCT00309387</nct_id>
  </id_info>
  <brief_title>Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)</brief_title>
  <acronym>CTNS</acronym>
  <official_title>Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Eye Institute (NEI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related
      Cataract (CTNS) is a 13-year study designed primarily to evaluate the safety and efficacy of
      a vitamin-mineral supplement (Centrum) containing recommended daily-allowance dosage (RDA) in
      preventing age-related cataract or delaying its progression in participants with early or no
      cataract at baseline.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite dramatic increase in the rates of cataract surgery during the last decades,
      age-related cataract is still responsible for about 50% of cases of severe visual impairment
      in developing countries, and for high and growing health care costs in western countries.
      CTNS was designed to complement the U.S. Age-Related Eye Disease Study (AREDS) by evaluating
      a much broader spectrum of nutrients at RDA dosages. Whereas about 60% of the AREDS control
      group was taking RDA dose multivitamin supplements, none of the participants in CTNS had
      taken any type of nutritional supplement for at least one year before the qualification
      visit. Therefore, the CTNS will be able to evaluate the effect of RDA doses versus no
      supplementation at all. CTNS and AREDS will use similar procedures, including those for
      grading the presence and severity of lens changes.

      CTNS is a randomized,parallel group, placebo controlled, double blinded, single center,
      intervention trial.

      Primary Outcomes: photographic evaluation of a prespecified increase from baseline in
      nuclear, cortical, or posterior subcapsular cataract (PSC) opacity grades or cataract
      surgery.

      Secondary Outcomes: increase in type-specific opacity grade, cataract surgery, and visual
      acuity loss from baseline &gt; or = 15 letters.

      Patients will be followed for a maximum of 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1995</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up</measure>
    <time_frame>at yearly intervals from baseline for approximately ten years</time_frame>
    <description>number of participants in whom any of the following occur in at least one eligible eye during follow-up: cataract surgery; nuclear opacity: a 1.5 U increase in opalescence from baseline; cortical opacity: a 10% increase in area within a standard 5 mm circle area of the lens from baseline; posterior subcapsular opacity: a 5% increase in area within a standard 5 mm circle area of the lens from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Showing Development or Progression of Nuclear Lens Opacities</measure>
    <time_frame>at yearly intervals from baseline for approximately ten years</time_frame>
    <description>number of participants with a 1.5 U increase in nuclear opalescence from baseline in at least one eligible eye during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Showing Development or Progression of Cortical Lens Opacities</measure>
    <time_frame>at yearly intervals from baseline for approximately ten years</time_frame>
    <description>Number of participants with a 10% increase in area of cortical opacity within a standard central 5 mm circle of the lens from baseline in at least one eligible eye during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Showing Development or Progression of Posterior Subcapsular Opacities</measure>
    <time_frame>at yearly intervals from baseline for approximately ten years</time_frame>
    <description>Number of participants with a 5% increase in area of posterior subcapsular opacity within a standard central 5 mm circle of the lens from baseline in at least one eligible eye during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Undergoing Cataract Surgery</measure>
    <time_frame>at 6 month intervals from baseline for approximately 10 yrs</time_frame>
    <description>number of participants undergoing cataract surgery in at least one eligible eye during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Decrease in Visual Acuity</measure>
    <time_frame>at 6 month intervals from baseline for approximately 10 yrs</time_frame>
    <description>Number of participants with a decrease in best corrected visual acuity score from baseline of &gt; 15 letters in at least one eligible eye during follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1020</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Centrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multivitamin-mineral supplement. RDA dosage. 1 tablet a day for the whole study duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pills. One tablet a day for the whole study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Centrum</intervention_name>
    <description>Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).</description>
    <arm_group_label>Centrum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablets manufactured to mimic Centrum tablets.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and photographic diagnosis of early or no age-related cataract

          -  Participants with early cataract must have at least one eligible eye with VA score
             20/32 or better

          -  Participants with no cataract must have VA score 20/32 or better in both eyes.

        Exclusion Criteria:

          -  Advanced cataract

          -  Bilateral aphakia or pseudophakia

          -  Any ocular disease or condition that might complicate the future evaluation of
             cataract

          -  Regular use of nutritional supplements

          -  Failure to take at least 75% of run-in medication

          -  Cancer with evidence of recurrence in the past 5 years

          -  Major cerebral or cardiovascular events in past 12 months

          -  Current participation to other clinical trials

          -  Any condition likely to prevent adherence to CTNS follow-up schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Maraini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Parma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert D Sperduto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Eye Institute (NEI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dpt. Scienze Otorino-Odonto Oftalmologiche, University of Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>CTNS Study Group. The Italian-American Clinical Trial of Nutritional Supplements and Age-Related Cataract (CTNS): design implications. CTNS report no. 1. Control Clin Trials. 2003 Dec;24(6):815-29.</citation>
    <PMID>14662284</PMID>
  </reference>
  <results_reference>
    <citation>Ferrigno L, Aldigeri R, Rosmini F, Sperduto RD, Maraini G; Italian-American Cataract Study Group. Associations between plasma levels of vitamins and cataract in the Italian-American Clinical Trial of Nutritional Supplements and Age-Related Cataract (CTNS): CTNS Report #2. Ophthalmic Epidemiol. 2005 Apr;12(2):71-80.</citation>
    <PMID>16019690</PMID>
  </results_reference>
  <results_reference>
    <citation>Clinical Trial of Nutritional Supplements and Age-Related Cataract Study Group, Maraini G, Williams SL, Sperduto RD, Ferris F, Milton RC, Clemons TE, Rosmini F, Ferrigno L. A randomized, double-masked, placebo-controlled clinical trial of multivitamin supplementation for age-related lens opacities. Clinical trial of nutritional supplements and age-related cataract report no. 3. Ophthalmology. 2008 Apr;115(4):599-607.e1. doi: 10.1016/j.ophtha.2008.01.005.</citation>
    <PMID>18387406</PMID>
  </results_reference>
  <results_reference>
    <citation>Maraini G, Williams SL, Sperduto RD, Ferris FL, Milton RC, Clemons TE, Rosmini F, Ferrigno L. Effects of multivitamin/mineral supplementation on plasma levels of nutrients. Report No. 4 of the Italian-American clinical trial of nutritional supplements and age-related cataract. Ann Ist Super Sanita. 2009;45(2):119-27.</citation>
    <PMID>19636163</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2006</study_first_posted>
  <results_first_submitted>March 28, 2012</results_first_submitted>
  <results_first_submitted_qc>March 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 24, 2012</results_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract</keyword>
  <keyword>Nutritional supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1020 participants were enrolled from January 8, 1996 through April 10, 1998 at the Institute of Ophthalmology of the University of Parma, Parma, Italy</recruitment_details>
      <pre_assignment_details>Potential participants had to complete a 1-month placebo run-in period (use of &gt; 75% of the run-in tablets) before randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="510"/>
                <participants group_id="P2" count="510"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="368"/>
                <participants group_id="P2" count="351"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="159"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="510"/>
            <count group_id="B2" value="510"/>
            <count group_id="B3" value="1020"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="371"/>
                    <measurement group_id="B2" value="370"/>
                    <measurement group_id="B3" value="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="4.82"/>
                    <measurement group_id="B2" value="67.7" spread="4.97"/>
                    <measurement group_id="B3" value="67.7" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="510"/>
                    <measurement group_id="B2" value="510"/>
                    <measurement group_id="B3" value="1020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up</title>
        <description>number of participants in whom any of the following occur in at least one eligible eye during follow-up: cataract surgery; nuclear opacity: a 1.5 U increase in opalescence from baseline; cortical opacity: a 10% increase in area within a standard 5 mm circle area of the lens from baseline; posterior subcapsular opacity: a 5% increase in area within a standard 5 mm circle area of the lens from baseline.</description>
        <time_frame>at yearly intervals from baseline for approximately ten years</time_frame>
        <population>Intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Centrum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up</title>
          <description>number of participants in whom any of the following occur in at least one eligible eye during follow-up: cataract surgery; nuclear opacity: a 1.5 U increase in opalescence from baseline; cortical opacity: a 10% increase in area within a standard 5 mm circle area of the lens from baseline; posterior subcapsular opacity: a 5% increase in area within a standard 5 mm circle area of the lens from baseline.</description>
          <population>Intention to treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Showing Development or Progression of Nuclear Lens Opacities</title>
        <description>number of participants with a 1.5 U increase in nuclear opalescence from baseline in at least one eligible eye during follow-up</description>
        <time_frame>at yearly intervals from baseline for approximately ten years</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Centrum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Showing Development or Progression of Nuclear Lens Opacities</title>
          <description>number of participants with a 1.5 U increase in nuclear opalescence from baseline in at least one eligible eye during follow-up</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Showing Development or Progression of Cortical Lens Opacities</title>
        <description>Number of participants with a 10% increase in area of cortical opacity within a standard central 5 mm circle of the lens from baseline in at least one eligible eye during follow-up</description>
        <time_frame>at yearly intervals from baseline for approximately ten years</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Centrum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Showing Development or Progression of Cortical Lens Opacities</title>
          <description>Number of participants with a 10% increase in area of cortical opacity within a standard central 5 mm circle of the lens from baseline in at least one eligible eye during follow-up</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Showing Development or Progression of Posterior Subcapsular Opacities</title>
        <description>Number of participants with a 5% increase in area of posterior subcapsular opacity within a standard central 5 mm circle of the lens from baseline in at least one eligible eye during follow-up</description>
        <time_frame>at yearly intervals from baseline for approximately ten years</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Centrum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Showing Development or Progression of Posterior Subcapsular Opacities</title>
          <description>Number of participants with a 5% increase in area of posterior subcapsular opacity within a standard central 5 mm circle of the lens from baseline in at least one eligible eye during follow-up</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Undergoing Cataract Surgery</title>
        <description>number of participants undergoing cataract surgery in at least one eligible eye during follow-up</description>
        <time_frame>at 6 month intervals from baseline for approximately 10 yrs</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Centrum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Undergoing Cataract Surgery</title>
          <description>number of participants undergoing cataract surgery in at least one eligible eye during follow-up</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Decrease in Visual Acuity</title>
        <description>Number of participants with a decrease in best corrected visual acuity score from baseline of &gt; 15 letters in at least one eligible eye during follow-up</description>
        <time_frame>at 6 month intervals from baseline for approximately 10 yrs</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Centrum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease in Visual Acuity</title>
          <description>Number of participants with a decrease in best corrected visual acuity score from baseline of &gt; 15 letters in at least one eligible eye during follow-up</description>
          <population>intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="363" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="397" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>hospitalization</sub_title>
                <counts group_id="E1" events="573" subjects_affected="286" subjects_at_risk="510"/>
                <counts group_id="E2" events="604" subjects_affected="316" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>upset stomach</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="510"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>increased weight</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="510"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="510"/>
              </event>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="510"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="510"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="510"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Giovanni Maraini, MD</name_or_title>
      <organization>University of Parma</organization>
      <phone>+39 0521 238527</phone>
      <email>maraini@unipr.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

